Glycomet 850 mg SR

Product Overview

Glycomet 850 mg SR is an extended‑release formulation of metformin, the first‑line oral agent for type 2 diabetes mellitus. Produced by USV Pvt Ltd, each strip contains ten tablets, each delivering 850 mg of the active ingredient. The product is marketed in pack sizes of 100, 200, and 300 tablets, offering flexibility for patients and clinicians seeking consistent glycemic control.

What is Glycomet 850 mg SR

Glycomet SR (Sustained Release) belongs to the biguanide class of antidiabetic drugs. The 850 mg strength is designed to release metformin gradually over approximately 24 hours, reducing peak plasma concentrations and minimizing gastrointestinal side effects. Metformin works by decreasing hepatic glucose production, improving peripheral insulin sensitivity, and enhancing peripheral glucose uptake.

According to the National Institutes of Health (NIH) and the American Diabetes Association (ADA), metformin remains the preferred initial pharmacologic therapy for most patients with type 2 diabetes because of its proven efficacy, safety profile, and cost‑effectiveness. Metformin details from NIH

Uses and Benefits

The primary indication for Glycomet 850 mg SR is the improvement of glycemic control in adults with type 2 diabetes when diet and exercise alone are insufficient. Clinical studies demonstrate that sustained‑release formulations provide comparable A1C reductions (approximately 1.5% to 2.0% over 24 weeks) with a lower incidence of nausea and diarrhea compared with immediate‑release metformin.

Additional benefits include potential weight neutrality, modest improvements in lipid parameters, and a reduced risk of hypoglycemia when used without sulfonylureas or insulin. These attributes make Glycomet SR a valuable option for patients who experience intolerable side effects from immediate‑release metformin or who require a once‑daily dosing regimen. FDA prescribing information and MedlinePlus overview provide further guidance.

How It Works

Metformin exerts its antidiabetic effect through multiple mechanisms:

• Inhibition of hepatic gluconeogenesis via AMP‑activated protein kinase (AMPK) activation.
• Increase in peripheral glucose uptake, especially in skeletal muscle.
• Reduction of intestinal absorption of glucose.
• Improvement of insulin signaling and sensitivity.

The sustained‑release matrix of Glycomet 850 mg SR ensures a slow, steady release of the drug, resulting in lower C_max and prolonged plasma exposure. This pharmacokinetics profile reduces the frequency of gastrointestinal adverse events and supports adherence to once‑daily dosing.

Dosage Guidelines

Typical initiation is 500 mg once daily, taken with the evening meal, followed by titration up to 850 mg once daily based on glycemic response and tolerability. The maximum recommended daily dose is 2,000 mg (two tablets of 850 mg) per the FDA labeling for patients with normal renal function (eGFR ≥45 mL/min/1.73 m²). Dose adjustments are required for patients with moderate renal impairment (eGFR 30‑44 mL/min/1.73 m²) and are contraindicated in severe renal impairment (eGFR <30 mL/min/1.73 m²).

Patients should be instructed to take the tablet whole, without crushing or chewing, to preserve the extended‑release characteristics. Regular monitoring of renal function and glycosylated hemoglobin (HbA1c) is recommended every 3‑6 months.

Side Effects

Most adverse reactions are mild to moderate and gastrointestinal in nature. Common side effects include:

• Nausea
• Diarrhea
• Abdominal discomfort
• Metallic taste
• Transient vitamin B12 deficiency with long‑term use

Rare but serious adverse events include lactic acidosis, particularly in patients with renal or hepatic impairment, acute heart failure, or conditions predisposing to hypoxia. Immediate medical attention is required if patients experience unexplained muscle pain, rapid breathing, abdominal pain, dizziness, or fatigue.

Warnings and Precautions

Before initiating therapy, assess renal function using estimated glomerular filtration rate (eGFR). Metformin is contraindicated in patients with eGFR <30 mL/min/1.73 m² and should be used with caution in those with eGFR 30‑44 mL/min/1.73 m², with a recommended maximum daily dose of 1,000 mg.

Patients should avoid excessive alcohol consumption and certain imaging contrast agents (e.g., iodinated contrast) that may increase the risk of lactic acidosis. Caution is advised in elderly patients, who may have reduced renal reserve, and in those with hepatic disease, congestive heart failure, or hypoxia.

Pregnant or breastfeeding women should consult a healthcare professional before use; metformin is generally considered safe in pregnancy, but dosage and monitoring must be individualized.

Frequently Asked Questions

1. What is the difference between Glycomet 850 mg SR and immediate‑release metformin? Glycomet SR provides a controlled, 24‑hour release of metformin, allowing once‑daily dosing and reducing peak drug levels, which may lower gastrointestinal side effects.
2. Can Glycomet SR be taken with other diabetes medications? It can be combined with sulfonylureas or insulin, but dosage adjustments are necessary to avoid hypoglycemia. Always consult a clinician before combining therapies.
3. How long does it take to see a reduction in HbA1c? Clinical trials show measurable A1C reductions after 12‑24 weeks of consistent use, with maximal effect typically observed at 24‑26 weeks.
4. Is vitamin B12 monitoring required? Long‑term metformin therapy can lead to decreased vitamin B12 levels. Periodic blood tests are recommended, especially in patients with neuropathy or anemia.
5. What should I do if I miss a dose? Take the missed dose as soon as remembered unless it is near the time of the next scheduled dose; then skip the missed dose and resume the regular schedule. Do not double‑dose.

For more detailed prescribing information, refer to the FDA’s drug label for metformin extended‑release or consult a qualified healthcare professional.

Related Products

• Erytop Gel (Clindamycin)
• Okamet 500 Mg (Metformin)
• Angispan TR (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 2.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 6.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)